<DOC>
	<DOC>NCT00744471</DOC>
	<brief_summary>The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients</brief_summary>
	<brief_title>Tanezumab in Osteoarthritis Of The Hip</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Hip</mesh_term>
	<criteria>Osteoarthritis of the hip according to ACR criteria with KellgrenLawrence xray grade of 2 Unwilling or unable to take nonopiate pain medications, for whom nonopiate pain medications have not provided adequate pain relief or are candidates for Hip injections, arthroplasty or replacement surgery Pain level and function levels as required by the protocol at Screening and Baseline Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study Must agree to the contraceptive requirements of the protocol if applicable Must agree to the treatment plan, scheduled visits, and procedures of the protocol Pregnancy BMI greater than 39 Other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>monoclonal antibody RN624 PF-04383119 nerve growth factor anti-nerve growth OA</keyword>
</DOC>